TreatmentUpdate
215
May/June 2016
Table of Contents
- Anti-hepatitis C drugs
- New drugs, wider range of genotypes, more cures
- Know your drugs and classes
- When HCV treatment failure occurs
- Child-Turcotte-Pugh – Grading severe liver disease and the likelihood of survival
- ABT-493 + ABT-530 – Eight-week treatment in genotypes 1 or 2 without cirrhosis
- ABT-493 + ABT-530 in genotype 3 with cirrhosis
- ABT-493 + ABT-530 – Eight-week treatment in genotype 3 without cirrhosis
- ABT-493 + ABT-530 in genotypes 4, 5 and 6
- ABT-493 + ABT-530 in genotype 1 with previous DAA therapy failure
- France – Events after cure of HCV
- U.S. study looks at long-term durability of cure, risk of relapse and liver cancer
